An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

• Published in: International journal of molecular sciences Vol. 20; no. 8; p. 1822
• Main Authors: Chu, Dinh-Toi, Bac, Nguyen Duy, Nguyen, Khanh-Hoang, Tien, Nguyen Le Bao, Thanh, Vo Van, Nga, Vu Thi, Ngoc, Vo Truong Nhu, Anh Dao, Duong Thi, Hoan, Le Ngoc, Hung, Nguyen Phuc, Trung Thu, Nguyen Thi, Pham, Van-Huy, Vu, Le Nguyen, Pham, Thuy Anh Vu, Thimiri Govinda Raj, Deepak B
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12.04.2019; MDPI
• Subjects: Ablation; anti-CD137 antibodies; anti-CD137 antibody therapy; Antigens; Antitumor activity; Binding sites; cancer immunotherapies; Cancer therapies; CD137 antigen; CD137/4-1BB; CD137L/4-1BBL; CD95 antigen; Cell activation; Cell cycle; Cell surface; Clinical trials; Cyclin-dependent kinases; Cytokines; Cytotoxicity; Endothelial cells; Fas antigen; Immune system; Immunoglobulins; Immunological memory; Immunotherapy; Kinases; Ligands; Lymphocyte receptors; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; MAP kinase; Memory cells; Monoclonal antibodies; NF-κB protein; Perforin; Proteins; Review; TRAF2 protein; Tumor cells; Tumor necrosis factor receptors; Tumor necrosis factor-TNF; Tumors; anti-CD137 antibodies; cancer immunotherapies; CD137L/4-1BBL; CD137/4-1BB; anti-CD137 antibody therapy
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20081822

The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.